As per attachment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines reported Q1 FY26 revenue from operations of ₹145.66 lakhs, nearly doubling from ₹72.49 lakhs in Q1 FY25 — a jump of about 101% year-on-year. Total income stood at ₹148.04 lakhs versus ₹73.65 lakhs last year. However, the company continued to post a loss, with a profit after tax (PAT) of -₹31.04 lakhs, slightly better than the -₹36.62 lakhs loss in Q1 FY25. Total expenses rose to ₹179.08 lakhs from ₹110.27 lakhs, driven mainly by higher material costs. EPS for the quarter was -₹0.31 compared to -₹0.37 in the same quarter last year. The statutory auditor issued a clean limited review report with no qualifications or concerns raised.
Strong top-line growth is a positive signal, but the company is still loss-making at both operating and net levels, so shareholders should watch whether revenue growth translates into profitability in coming quarters. No near-term positive surprises for the stock price given persistent losses.